MARKET

SPRB

SPRB

Spruce Biosciences, Inc.
NASDAQ
49.98
+0.95
+1.94%
Opening 12:08 06/10 EDT
OPEN
48.53
PREV CLOSE
49.03
HIGH
50.38
LOW
48.53
VOLUME
17.41K
TURNOVER
--
52 WEEK HIGH
240.00
52 WEEK LOW
4.350
MARKET CAP
137.56M
P/E (TTM)
-1.3048
1D
5D
1M
3M
1Y
5Y
1D
Toll Brothers upgraded, Lennar downgraded: Wall Street’s top analyst calls
TipRanks · 1d ago
Spruce Biosciences Initiated at Buy by Jones Trading
Dow Jones · 1d ago
Spruce Biosciences Price Target Announced at $135.00/Share by Jones Trading
Dow Jones · 1d ago
Jones Trading Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $135
Benzinga · 1d ago
Spruce Biosciences initiated with a Buy at JonesResearch
TipRanks · 2d ago
Spruce says long-term TA-ERT data presented at MPS Symposium
TipRanks · 2d ago
Spruce Biosciences Presents Data Demonstrating Long-Term Benefit Of Tralesinidase Alfa Enzyme Replacement Therapy In Patients With Sanfilippo Syndrome Type B At 18th International MPS Symposium
Benzinga · 2d ago
Spruce Biosciences reports six-year tralesinidase alfa data showing sustained biomarker reductions, stabilized cognition in MPS IIIB
PUBT · 2d ago
More
About SPRB
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for neurological disorders with significant unmet medical need. It has a diverse portfolio of product candidates addressing diseases with high unmet medical need and clear biology for treatment, for which there are either no approved therapies treating the underlying disease or suboptimal treatment options. Its pipeline consists of TA-ERT, Tildacerfont and Cortibon, and SPR202. TA-ERT is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase. TA-ERT is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB who lack rhNAGLU enzyme activity. Tildacerfont has the potential to address hyperactive brain corticotropin-releasing factors neurotransmission and aberrant functioning of the hypothalamus-pituitary-adrenal axis in patients with MDD. SPR202 focuses on the treatment of Congenital Adrenal Hyperplasia and other indications.

Webull offers Spruce Biosciences, Inc stock information, including NASDAQ: SPRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SPRB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SPRB stock methods without spending real money on the virtual paper trading platform.